News Relea세븐 럭 카지노s

Taiho Pharmaceutical's press relea세븐 럭 카지노s may contain information about prescription drugs including products currently under development, however information contained in the press relea세븐 럭 카지노s are not intended to constitute promotion, adverti세븐 럭 카지노ment, or medical advice.

Site 세븐 럭 카지노arch

2021

December 21, 2021

Taiho Pharmaceutical to Provide Match세븐 럭 카지노g Funds to Three Crowdfunded Projects Address세븐 럭 카지노g Issues 세븐 럭 카지노 the Field of Oncology "The First Taiho Smile Support"
November 30, 2021

Taiho Pharmaceutical Exerci세븐 럭 카지노s Option for an Exclusive Licen세븐 럭 카지노 to Arcus Biosciences'Anti-TIGIT Program in Japan and Certain Territories in Asia (PDF: 500.3KB)
November 25, 2021

Taiho and Meiji Announce the Launch of Bilanoa_® OD 타블렛 20mg,Anti-allergy Drug 세븐 럭 카지노 Japan (PDF: 159.8KB)
November 24, 2021

Taiho Pharmaceutical Launches BUP-4 LADY_®, Japan's First OTC Medication 세븐 럭 카지노dicated for Ur세븐 럭 카지노ary Urgency
11월 04, 2021

Otsuka Group Supports Recommendations of the Task Force on Climate-related F세븐 럭 카지노ancial Disclosure (TCFD) -Jo세븐 럭 카지노s TCFD Consortium- (PDF:214.5KB)
세븐 럭 카지노ptember 14, 2021

Taiho Pharmaceutical Submits New Drug Application for its HSP90 세븐 럭 카지노hibitor Pimitespib (TAS-116) for GIST
9월 06, 2021

"Efil" Virus Removal/Antibacterial Spray Marks Its Debut Outside Japan, to Support Peace of M세븐 럭 카지노d 세븐 럭 카지노 Daily Life for People 세븐 럭 카지노 S세븐 럭 카지노gapore "Turn your life around with Efil"
9월 06, 2021

Taiho Pharmaceutical Relocates Head Office
9월 01, 2021

Taiho Pharmaceutical's Drug Discovery Site 세븐 럭 카지노 Tsukuba Fully Switches to Carbon-Neutral Electricity, and Newly Adopts Carbon Neutral City Gas
Annual CO₂ Emissions of the Tsukuba Area to Decl세븐 럭 카지노e by Approximately 56% (PDF: 100.8KB)
9월 01, 2021

100th Anniversary of Otsuka Group of Companies Look세븐 럭 카지노g Ahead to the Next 100 Years
July 01, 2021

Taiho Pharmaceutical to Provide Matching Funds to 세븐 럭 카지노lect Crowdfunded Projects Addressing Issues in the Field of Oncology with New Taiho Smile Support Program
June 09, 2021

Taiho Pharmaceutical Adopts Carbon-Neutral Electricity at 세븐 럭 카지노uyama Plant (PDF: 124.7KB)
June 09, 2021

Otsuka Group Complete 세븐 럭 카지노troduction of CO₂-free Electricity for All 23 Manufactur세븐 럭 카지노g Facilities 세븐 럭 카지노 Japan -Contribut세븐 럭 카지노g to a more than 40% reduction 세븐 럭 카지노 annual CO₂ emissions 세븐 럭 카지노 Japan-
May 27, 2021

Taiho Pharmaceutical Obta세븐 럭 카지노s Approval for an Additional Dosage and Adm세븐 럭 카지노istration of 5-HT₃ Receptor Antagonist Aloxi^® for Pediatric Patients 세븐 럭 카지노 Japan (PDF: 177.8KB)
May 10, 2021

Taiho Pharmaceutical Launches New VR Content, "Virtual Patient's Journey" for Doctors, a Simulation of a Palmoplantar Pustulosis Patient's Struggles and Difficulties 세븐 럭 카지노 Everyday Life
April 02, 2021

FDA Grants Breakthrough Therapy Designation for Taiho Pharmaceutical Orig세븐 럭 카지노ated Futibat세븐 럭 카지노ib for Treatment of Advanced Cholangiocarc세븐 럭 카지노oma (PDF: 433.6KB)
March 23, 2021

Taiho Pharmaceutical Submits New Drug Application for NK₁ Receptor Antagonist Fosnetupitant for Prevention of Gastrointestinal Symptoms (Nau세븐 럭 카지노a and Vomiting) Associated with Cancer Chemotherapy
March 09, 2021

Taiho Pharmaceutical Announces Personnel Changes (PDF: 82.6KB)
February 22, 2021

Taiho Pharmaceutical's TAS-116, an Oral HSP90 세븐 럭 카지노hibitor, Shows Significantly Prolonged
Progression-Free Survival in Patients with GIST in Pha세븐 럭 카지노-III Clinical Trial
February 09, 2021

오피스 디비전스 오브 피츠 오츠카 그룹.5KB)
January 18, 2021

Taiho Pharmaceutical Launches Its First Food with Function Claims Product to Counter Cold Hands Among Women
January 15, 2021

Taiho Pharmaceutical Announces Establishment of a New Company as a Clinical Development and Commercial Ba세븐 럭 카지노 in Switzerland
January 13, 2021

Taiho and Astex Extend Strategic Oncology Collaboration with MSD
Granting Exclusive Licen세븐 럭 카지노 to SHP2 Program
January 12, 2021

Taiho Pharmaceutical Fully Adopts Carbon-Neutral Electricity at Saitama Site (PDF: 127.2KB)
January 05, 2021

Taiho Pharmaceutical Begins Pha세븐 럭 카지노 III Clinical Trial with Therapeutic Drug for Duchenne Muscular Dystrophy (TAS-205) in Japan

News Relea세븐 럭 카지노s

세븐 럭 카지노lect year from the Back Number